• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?

作者信息

Jankovic Joseph

机构信息

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, Texas 77030-4202, USA.

出版信息

Nat Rev Neurol. 2017 Nov;13(11):643-644. doi: 10.1038/nrneurol.2017.140. Epub 2017 Sep 29.

DOI:10.1038/nrneurol.2017.140
PMID:28960185
Abstract
摘要

相似文献

1
Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?帕金森病：艾塞那肽——一种治疗糖尿病和帕金森病的药物？
Nat Rev Neurol. 2017 Nov;13(11):643-644. doi: 10.1038/nrneurol.2017.140. Epub 2017 Sep 29.
2
[Parkinson disease. Value of COMT inhibitors is verified].[帕金森病。儿茶酚-O-甲基转移酶抑制剂的价值得到验证]
MMW Fortschr Med. 2001 May 3;143(18):51.
3
Is Exenatide a Treatment for Parkinson's Disease?艾塞那肽是帕金森病的一种治疗方法吗？
J Parkinsons Dis. 2017;7(3):451-458. doi: 10.3233/JPD-171192.
4
Post hoc analysis of the Exenatide-PD trial-Factors that predict response.依西那肽-PD 试验的事后分析-预测应答的因素。
Eur J Neurosci. 2019 Feb;49(3):410-421. doi: 10.1111/ejn.14096. Epub 2018 Oct 6.
5
Parkinson's disease.帕金森病。
Clin Evid. 2002 Jun(7):1208-20.
6
Drugs for Parkinson's disease.治疗帕金森病的药物。
J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):607-10. doi: 10.1136/jnnp.73.6.607.
7
Clinical trials of neuroprotection for Parkinson's disease.帕金森病神经保护的临床试验。
Neurology. 2004 Oct 12;63(7 Suppl 2):S23-31. doi: 10.1212/wnl.63.7_suppl_2.s23.
8
Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease.氢气水治疗帕金森病的随机、双盲、多中心试验。
Mov Disord. 2018 Sep;33(9):1505-1507. doi: 10.1002/mds.27472. Epub 2018 Sep 12.
9
Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus.GLP-1 类似物：甘精胰岛素联合治疗猫糖尿病的安全性和疗效评估。
Domest Anim Endocrinol. 2018 Oct;65:80-89. doi: 10.1016/j.domaniend.2018.04.003. Epub 2018 May 9.
10
Parkinson disease and growth factors - is GDNF good enough?帕金森病与生长因子——胶质细胞源性神经营养因子是否足够有效？
Nat Rev Neurol. 2019 Jun;15(6):312-314. doi: 10.1038/s41582-019-0180-6.

引用本文的文献

1
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis.胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂对神经退行性疾病基于药效学的预防作用：网状Meta分析证据
BMC Med. 2025 Apr 7;23(1):197. doi: 10.1186/s12916-025-04018-w.
2
Functionalized lipid nanoparticles modulate the blood-brain barrier and eliminate α-synuclein to repair dopamine neurons.功能化脂质纳米颗粒调节血脑屏障并清除α-突触核蛋白以修复多巴胺能神经元。
Asian J Pharm Sci. 2024 Apr;19(2):100904. doi: 10.1016/j.ajps.2024.100904. Epub 2024 Mar 12.
3

本文引用的文献

1
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.每周一次依替巴肽对比安慰剂治疗帕金森病：一项随机、双盲、安慰剂对照试验。
Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3.
2
Is Exenatide a Treatment for Parkinson's Disease?艾塞那肽是帕金森病的一种治疗方法吗？
J Parkinsons Dis. 2017;7(3):451-458. doi: 10.3233/JPD-171192.
3
Progress toward an integrated understanding of Parkinson's disease.对帕金森病综合理解的进展。
Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues.
以神经退行性疾病为重点的治疗性药物重新定位：威胁与问题
Front Pharmacol. 2022 Oct 3;13:1007315. doi: 10.3389/fphar.2022.1007315. eCollection 2022.
4
A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease.一种 GLP1 受体激动剂糖尿病药物可改善婴儿神经代谢疾病小鼠模型中的神经退行性变。
Sci Rep. 2022 Aug 15;12(1):13825. doi: 10.1038/s41598-022-17338-1.
5
Diabetes mellitus and Parkinson's disease: dangerous liaisons between insulin and dopamine.糖尿病与帕金森病：胰岛素与多巴胺之间的危险关联
Neural Regen Res. 2022 Mar;17(3):523-533. doi: 10.4103/1673-5374.320965.
6
Research and prospect of peptides for use in obesity treatment (Review).用于肥胖症治疗的肽类研究与展望（综述）
Exp Ther Med. 2020 Dec;20(6):234. doi: 10.3892/etm.2020.9364. Epub 2020 Oct 16.
7
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease-Viewpoint.二甲双胍作为前驱期帕金森病潜在神经保护剂的观点
Front Neurol. 2020 Jun 12;11:556. doi: 10.3389/fneur.2020.00556. eCollection 2020.
8
Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment.胰高血糖素样肽（GLP-1）在突触核蛋白病治疗中的前景。
Mov Disord Clin Pract. 2018 Apr 15;5(3):255-258. doi: 10.1002/mdc3.12611. eCollection 2018 May-Jun.
9
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.PT302 是一种长效 Exendin-4 缓释制剂，治疗后可减少帕金森病 6-羟多巴胺大鼠模型中的多巴胺能神经退行性变。
Sci Rep. 2018 Jul 16;8(1):10722. doi: 10.1038/s41598-018-28449-z.
10
Old Drugs as New Treatments for Neurodegenerative Diseases.老药作为神经退行性疾病的新疗法
Pharmaceuticals (Basel). 2018 May 11;11(2):44. doi: 10.3390/ph11020044.
F1000Res. 2017 Jul 12;6:1121. doi: 10.12688/f1000research.11820.1. eCollection 2017.
4
Insulin resistance and exendin-4 treatment for multiple system atrophy.胰岛素抵抗与艾塞那肽-4治疗多系统萎缩
Brain. 2017 May 1;140(5):1420-1436. doi: 10.1093/brain/awx044.
5
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease.线粒体丙酮酸载体调控帕金森病实验模型中的自噬、炎症和神经退行性变。
Sci Transl Med. 2016 Dec 7;8(368):368ra174. doi: 10.1126/scitranslmed.aag2210.
6
New and emerging medical therapies in Parkinson's disease.帕金森病的新型及新兴医学疗法
Expert Opin Pharmacother. 2016;17(7):895-909. doi: 10.1517/14656566.2016.1149163. Epub 2016 Feb 19.
7
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.吡格列酮用于早期帕金森病：一项2期、多中心、双盲、随机试验。
Lancet Neurol. 2015 Aug;14(8):795-803. doi: 10.1016/S1474-4422(15)00144-1. Epub 2015 Jun 23.
8
Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy.通过改善身体和大脑生物能量代谢来降低帕金森病风险及进行治疗的干预措施。
J Parkinsons Dis. 2014;4(1):1-13. doi: 10.3233/JPD-130335.
9
Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies.糖尿病与帕金森病风险：病例对照研究的最新荟萃分析
PLoS One. 2014 Jan 21;9(1):e85781. doi: 10.1371/journal.pone.0085781. eCollection 2014.
10
Exenatide and the treatment of patients with Parkinson's disease.依西那肽与帕金森病患者的治疗。
J Clin Invest. 2013 Jun;123(6):2730-6. doi: 10.1172/JCI68295.